Journal of Controlled Release,
Год журнала:
2025,
Номер
380, С. 348 - 361
Опубликована: Фев. 8, 2025
Staphylococcus
aureus
(S.
aureus)
infections,
especially
methicillin
resistant
(MRSA),
constitute
an
alarming
public
health
issue
due
to
its
association
with
high
mortality,
morbidity,
and
hospitalization
costs.
The
increasing
antibiotic
resistance
biofilm-associated
infections
of
MRSA
prompted
the
discovery
novel
more
effective
therapeutic
strategies.
Our
team
has
been
working
on
alternative
therapies
against
S.
infections.
For
this,
we
have
repurposing
existing
antibacterial
drug,
rifabutin
(RFB),
through
a
nanotechnological
platform,
liposomes,
aiming
promote
preferential
targeting
infected
sites
maximizing
potential
effect.
RFB
formulations
commercial
strain
(MRSA
ATCC®-33592),
either
in
planktonic
or
biofilm
forms,
was
assessed.
displayed
higher
effects
towards
than
vancomycin
(VCM),
gold
standard
treatment
MBIC50
values
103
>
800
μg/ml,
respectively.
Moreover,
antimicrobial
effect
RFB-loaded
liposomes
demonstrated
be
lipid
composition-dependent
based
MIC50
values,
which
also
confirmed
by
confocal
laser
scanning
microscopy.
These
studies
supported
that
for
positively
charged
electrostatic
interaction
at
surface
occurs
without
internalization.
On
other
hand,
neutral
charge
internalization
within
observed.
this
liposomal
formulation
stable
human
plasma,
as
83
%
still
associated
24
h
after
incubation
37
°C.
proof
concept
assessed
systemic
murine
models
infection.
Therapeutic
survival
rates
were
evaluated
animals
induced
treated
free
forms
compared
negative
positive
controls.
lower
infection
model,
100
achieved
all
groups
under
study.
However,
model
only
group
incorporated
attained.
In
terms
bacterial
burden,
exhibited
levels
when
VCM,
even
using
dose:
20
vs
40
mg/kg
body
weight,
Overall,
constitutes
strategy
being
potentiated
nanoplatform.
Applied Sciences,
Год журнала:
2024,
Номер
14(18), С. 8137 - 8137
Опубликована: Сен. 10, 2024
Biofilm-associated
infections
present
a
significant
challenge
in
modern
medicine,
primarily
due
to
their
resilience
and
resistance
conventional
treatments.
These
occur
when
bacteria
form
biofilms,
protective
layers
formed
by
bacterial
communities,
which
are
notoriously
resistant
traditional
antibiotics
on
surfaces
such
as
medical
implants
biological
surfaces,
making
eradication
with
standard
difficult.
This
leads
persistent
infections,
imposing
substantial
economic
burden
healthcare
systems.
The
urgency
find
alternative
treatments
is
critical
current
methods
insufficient
costly.
Innovative
approaches,
nanotechnology-based
therapies,
offer
promising
alternatives
targeting
biofilms
more
effectively
reducing
the
need
for
invasive
procedures.
Nanocarriers
hold
promise
fight
against
biofilm-associated
infections.
can
penetrate
than
treatments,
delivering
higher
concentrations
of
or
other
antimicrobial
agents
precisely
where
they
needed.
targeted
approach
not
only
enhances
efficacy
but
also
minimizes
potential
side
effects.
development
nanocarrier-based
therapies
crucial
overcoming
limitations
ultimately
improving
patient
outcomes
In
this
review,
systems,
characteristics,
limitations,
benefits
explored
address
biofilms-related
Additionally,
biofilm
evaluation
models
tests
necessary
preclinical
validation
these
nanosystems
facilitate
clinical
application
addressed.
Journal of Controlled Release,
Год журнала:
2025,
Номер
380, С. 348 - 361
Опубликована: Фев. 8, 2025
Staphylococcus
aureus
(S.
aureus)
infections,
especially
methicillin
resistant
(MRSA),
constitute
an
alarming
public
health
issue
due
to
its
association
with
high
mortality,
morbidity,
and
hospitalization
costs.
The
increasing
antibiotic
resistance
biofilm-associated
infections
of
MRSA
prompted
the
discovery
novel
more
effective
therapeutic
strategies.
Our
team
has
been
working
on
alternative
therapies
against
S.
infections.
For
this,
we
have
repurposing
existing
antibacterial
drug,
rifabutin
(RFB),
through
a
nanotechnological
platform,
liposomes,
aiming
promote
preferential
targeting
infected
sites
maximizing
potential
effect.
RFB
formulations
commercial
strain
(MRSA
ATCC®-33592),
either
in
planktonic
or
biofilm
forms,
was
assessed.
displayed
higher
effects
towards
than
vancomycin
(VCM),
gold
standard
treatment
MBIC50
values
103
>
800
μg/ml,
respectively.
Moreover,
antimicrobial
effect
RFB-loaded
liposomes
demonstrated
be
lipid
composition-dependent
based
MIC50
values,
which
also
confirmed
by
confocal
laser
scanning
microscopy.
These
studies
supported
that
for
positively
charged
electrostatic
interaction
at
surface
occurs
without
internalization.
On
other
hand,
neutral
charge
internalization
within
observed.
this
liposomal
formulation
stable
human
plasma,
as
83
%
still
associated
24
h
after
incubation
37
°C.
proof
concept
assessed
systemic
murine
models
infection.
Therapeutic
survival
rates
were
evaluated
animals
induced
treated
free
forms
compared
negative
positive
controls.
lower
infection
model,
100
achieved
all
groups
under
study.
However,
model
only
group
incorporated
attained.
In
terms
bacterial
burden,
exhibited
levels
when
VCM,
even
using
dose:
20
vs
40
mg/kg
body
weight,
Overall,
constitutes
strategy
being
potentiated
nanoplatform.
